



RECEIVED
CENTRAL FAX CENTER

JUL 26 2004

OFFICIAL

Patent Technology Center 1600

Facsimile Transmission

To: Name: Official Fax
Company:
Fax Number: 7038729306
Voice Phone:

From: Name: (703) 872-9306
Official Fax Number: (703) 872-9307
Official After Final Fax Number: (703) 872-9307
Voice Phone:

37 C.F.R. 1.6 sets forth the types of correspondence that can be communicated to the Patent and Trademark Office via facsimile transmissions. Applicants are advised to use the certificate of facsimile transmission procedures when submitting a reply to a non-final or final Office action by facsimile (37 CFR 1.8(a)).

Fax Notes:

Date and time of transmission: Monday, July 26, 2004 5:18:20 PM
Number of pages including this cover sheet: 06



Legal Division
Pfizer Inc
10777 Science Center Drive
San Diego, CA 92121

FACSIMILE TRANSMISSION**NOTICE OF CONFIDENTIALITY**

This transmission is intended only for the use of the Addressee and may contain information that is: 1. Subject to attorney/client privilege; 2. Attorney work product; or 3. Confidential. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of the information contained in this facsimile is strictly unauthorized and prohibited. If you have received this facsimile in error, please notify us immediately by collect telephone call to the sender named below. Thank you.

To: Amendment, Commissioner For Patents

Location: P.O. Box 1450, Alexandria, VA 22313-1450

Facsimile Telephone: 571-273-0785

No. of Pages: (including cover sheet) 5 pages

From: Reena R. Desai

Department Name: Legal Division

Telephone: 858-526-4932

Date: July 26, 2004

MESSAGE:

Transmitted herewith are the following documents:

- | | |
|----------------------------------|---------------------|
| 1. Amendment and Response | 3 pages; and |
| 2. Transmittal Letter | 1 page. |

FAX COVERSHEET

PC19055E/AG0069-04
Response to Office Action

Certificate of Mailing (37 C.F.R. §1.8):
I hereby certify that this correspondence and all documents attached hereto are being sent via facsimile to Examiner Kim at 571-273-0785 on this 26th day of July 2004.

s/ Rachel Potash
Rachel Potash

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: M.A. MCTIGUE, et al.	Group Art Unit: 1637
Serial No.: 09/939,754	Examiner: KIM, YOUNG J.
Confirmation No.: 3837	
Filed: August 28, 2001	
For: MODIFICATIONS OF VEGF RECEPTOR-2 PROTEIN AND METHOD OF USE	

Mail Stop: Amendment
Honorable Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

- | | |
|---------------------------|----------|
| 1. Amendment and Response | 3 pages. |
|---------------------------|----------|

Respectfully submitted,

Date: July 26, 2004

Reena R. Desai
Reena R. Desai
Attorney for Applicants
Registration No. 53,833

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 526-4932
Fax: (858) 678-8233

RECEIVED

Jul-26-04 14:20 From-pfizer la jolla CENTRAL FAX CENTER

+8586788233

T-202 P.003/005 F-442

JUL 26 2004

PC19055E/AG0069-04

Serial No. 09/939,754

OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: M.A. McTigue et al.	Examiner: Y.J. Kim
Serial No.: 09/939,754 Conf. No.: 3837	Group Art Unit: 1637
Filed: August 28, 2001	Attorney Docket No.: PC19055E/AG0069-04
For: Modifications of VEGF Receptor-2 Protein and Method of Use	

Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL AMENDMENT AND RESPONSE UNDER 37 CFR 1.116

Sir:

In response to the final Office action mailed April 22, 2004, please amend the above-identified application as follows:

- Amendments to the Specification begin on page 2 of this paper.
- Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this paper.
- Amendments to the Drawings begin on page ____ of this paper and include both an attached replacement sheet and an annotated sheet showing changes.
- Remarks begin on page 3 of this paper.